This new 247-page report from VPGMarketResearch.com provides a comprehensive analysis of the French therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers.  The report provides test volume and sales forecasts by country and market segment for the following assays: Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Sirolimus, Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid and Vancomycin.During the next five years, the TDM market will undergo significant transformation.  These changes will be caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition.  Some segments will start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology.  This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others.“2016 France Therapeutic Drug Monitoring (TDM) Market” is a unique market and technology assessment designed to help... Research Beam Model: Research Beam Product ID: 339103 0 USD New
2016 France Therapeutic Drug Monitoring (TDM) Market: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers
 
 

2016 France Therapeutic Drug Monitoring (TDM) Market: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers

  • Category : Diagnostic and Biotech
  • Published On : October   2015
  • Pages : 247
  • Publisher : VPGMarketResearch.com
 
 
 

This new 247-page report from VPGMarketResearch.com provides a comprehensive analysis of the French therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. 

The report provides test volume and sales forecasts by country and market segment for the following assays: Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Sirolimus, Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid and Vancomycin.

During the next five years, the TDM market will undergo significant transformation.  These changes will be caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition.  Some segments will start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology.  This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others.

“2016 France Therapeutic Drug Monitoring (TDM) Market” is a unique market and technology assessment designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and developed effective strategic responses.  The study provides five-year forecasts for major TDM assays; compares features of leading analyzers; and profiles key competitors.            
      
Contains 247 pages and 17 tables

../toc/TOCTOT%20TDMMarketinFrance%20HospitalsCommercialLabs.pdf
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 
REQUEST SAMPLE    ASK FOR DISCOUNT